네덜란드 - 네덜란드어 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - triptorelineacetaat 0-water samenstelling overeenkomend met ; triptoreline - poeder en oplosmiddel voor suspensie voor injectie - dextraan 70 ; melkzuur(d,l)-glycolzuur copolymeer ; natriumchloride ; natriumdiwaterstoffosfaat 2-water (e 339) ; natriumhydroxide (e 524) ; polysorbaat 80 (e 433) ; propyleenglycoldicaprylocapraat ; water voor injectie - triptorelin

벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ipsen sa-nv - triptorelinepamoaat - eq. triptoreline 11,25 mg - poeder en oplosmiddel voor suspensie voor injectie - 11,25 mg - triptorelinepamoaat - triptorelin

벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ipsen sa-nv - triptorelinepamoaat 31 mg - eq. triptoreline 22,5 mg - poeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte - 22,5 mg - triptorelinepamoaat 31 mg - triptorelin

벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ferring sa-nv - triptorelineacetaat 4,12 mg/ml - eq. triptoreline 3,75 mg/ml - poeder en oplosmiddel voor suspensie voor injectie - 3,75 mg/ml - triptorelineacetaat 4.12 mg/ml - triptorelin

벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

opella healthcare belgium sa-nv - plantago lanceolata l., blad, vloeibaar extract 33,3 mg/ml - siroop - plantago lanceolata l., blad, droog extract 23.3 mg/ml - cough suppressants, excl. combinations with expectorants

유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft rejection - immunosuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

네덜란드 - 네덜란드어 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

theramex ireland limited 3rd floor, kilmore house, park lane, spencer dock d01 ye64 dublin 1 (ierland) - calciumcarbonaat (e 170) 2500 mg/stuk samenstelling overeenkomend met ; calcium (ca2+) 1000 mg/stuk - bruistablet - citroenzuur 0-water (e 330) ; dextrine ; gluconolacton (e 575) ; mandarijnolie ; mannitol (d-) (e 421) ; natriumcyclamaat (e 952) ; orange-mandarin natural flavour mk-500 (ri) ; saccharoide natrium x-water (e 954) ; sinaasappelolie ; sorbitol (d-)(e 420) ; zonnegeel fcf (e 110), - calcium carbonate

네덜란드 - 네덜란드어 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

theramex ireland limited 3rd floor, kilmore house, park lane, spencer dock d01 ye64 dublin 1 (ierland) - calciumcarbonaat (e 170) 1250 mg/stuk samenstelling overeenkomend met ; calcium (ca2+) 500 mg/stuk - bruistablet - citroenzuur 0-water (e 330) ; dextrine ; gluconolacton (e 575) ; mandarijnolie ; mannitol (d-) (e 421) ; natriumcyclamaat (e 952) ; orange-mandarin natural flavour mk-500 (ri) ; saccharoide natrium x-water (e 954) ; sinaasappelolie ; sorbitol (d-)(e 420) ; zonnegeel fcf (e 110), - calcium carbonate

유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

takeda manufacturing austria ag - menselijk eiwit c - purpura fulminans; protein c deficiency - antitrombotische middelen - ceprotin is indicated for prophylaxis and treatment of  purpura fulminans  coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.

유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

ablynx nv - caplacizumab - purpura, trombotische trombocytopenische - antitrombotische middelen - cablivi is geïndiceerd voor de behandeling van volwassenen met een aflevering van verworven trombotische trombocytopenische purpura (attp), in combinatie met plasma-uitwisseling en immunosuppressie.